Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glycopyrronium cloth, 2.4% · 1 trial · 1 indication
The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis \[score on a scale from 0 (better) -10 (worse)\].
| Arm | Type | Description |
|---|---|---|
| Group 1 Active | ACTIVE_COMPARATOR | Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove) |
| Group 1 Vehicle | PLACEBO_COMPARATOR | Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove) |
| Group 2 Active | ACTIVE_COMPARATOR | Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove) |
| Group 2 Vehicle | PLACEBO_COMPARATOR | Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove) |
| Group 3 Active | ACTIVE_COMPARATOR | Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes |
| Group 3 Vehicle | PLACEBO_COMPARATOR | Vehicle cloth applied to the hands once daily for 14 days: 15 minutes |
| Group 4 Active | ACTIVE_COMPARATOR | Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes |
| Group 4 Vehicle | PLACEBO_COMPARATOR | Vehicle cloth applied to the hands once daily for 14 days: 30 minutes |
| Name | Type | Description |
|---|---|---|
| Glycopyrronium cloth, 2.4% | DRUG | Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium |
| Vehicle | DRUG | Pre-saturated 100% polypropylene, nonwoven, fabric cloth |
Inclusion Criteria: 1. Signed informed consent and assent (for subjects under legal adult age). 2. Age ≥9 years. 3. Primary palmar hyperhidrosis for at least 6 months duration. 4. Average sweat severity score of ≥4 at Baseline. 5. Hyperhidrosis Disease Severity Scale of 3 or 4 at Baseline. 6. Willi...
Glycopyrronium cloth, 2.4% is an investigational topical small molecule being developed by Journey Medical Corporation for palmar hyperhidrosis, a condition of excessive sweating on the palms. It is applied as a cloth formulation and is in Phase 2 clinical development. It is not approved by the FDA.
Glycopyrronium cloth, 2.4% is being studied for the treatment of palmar hyperhidrosis, a dermatologic condition involving excessive sweating of the hands. The clinical program has focused on this indication, and the drug remains investigational rather than approved for any use.
Glycopyrronium cloth, 2.4% targets the muscarinic acetylcholine receptors CHRM1, CHRM2, CHRM3, CHRM4, and CHRM5. It acts as an antagonist at these receptors, blocking muscarinic signaling. This mechanism underlies its development as a topical treatment for excessive sweating in palmar hyperhidrosis.
Journey Medical Corporation, which trades under the ticker DERM, is developing glycopyrronium cloth, 2.4% for palmar hyperhidrosis. The company is the sponsor of the clinical program for this topical small molecule formulation.
Glycopyrronium cloth, 2.4% is in Phase 2 development. It is investigational and has not been approved by the FDA. The Phase 2 trial for palmar hyperhidrosis has been completed, and no trials are currently listed as active.
Glycopyrronium cloth, 2.4% has been evaluated in one completed Phase 2 trial, NCT03880266, titled A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis. The trial enrolled 72 participants in the United States, was randomized, double-blind, and placebo-controlled, and included patients aged 9 years and older.